Literature DB >> 1365670

Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat.

S R Wachtel1, R J Brooderson, F J White.   

Abstract

The present report investigated several parametric and pharmacological aspects of the enhanced self-grooming behavior of rats following systemic administration of the selective D1 dopamine (DA) receptor agonist SKF 38393. The amount of time that rats spent grooming themselves was measured continuously for 30 min following drug administration to provide a quantitative measure of the drug-induced behavior. SKF 38393 increased the amount of grooming in a dose-dependent manner (0.5-16 mg/kg, SC). The onset of this effect required at least 5 min and it persisted for at least 60 min. The ability of SKF 38393 to enhance grooming was shared by R-SKF 38393, but not S-SKF 38393, consistent with the affinities of these enantiomers for the D1 DA receptor. Unlike SKF 38393, the peripheral D1 agonist fenoldopam (SKF82526) failed to cause an increased grooming response, suggesting a central site of action for elicitation of this behavior. The SKF 38393-induced increase in grooming was competitively antagonized by the D1 selective antagonist SCH 23390 (0.5 mg/kg, SC). Although the D2 DA receptor-selective antagonist eticlopride reduced SKF 38393-elicited grooming, this antagonism appeared to be of a physiological rather than pharmacological nature. When eticlopride was coadministered with the non-selective (mixed) D1/D2 agonist apomorphine, an increase in grooming behavior similar to that produced by SKF 38393 was observed. Inactivation of D1 and D2 DA receptors produced by pretreatment with the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), at a dose which reduces D1 and D2 receptor density by > or = 50% (8.0 mg/kg, IP), reduced SKF 38393-induced grooming by approximately 50%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365670     DOI: 10.1007/bf02245478

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.

Authors:  R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

2.  Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK & F 38393 and its R- and S-enantiomers in the intact adult rat.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Developmental and age-related changes in D1-dopamine receptors and dopamine content in the rat striatum.

Authors:  O Giorgi; G De Montis; M L Porceddu; S Mele; G Calderini; G Toffano; G Biggio
Journal:  Brain Res       Date:  1987-10       Impact factor: 3.252

4.  Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Quantitative autoradiographical analysis of the age-related modulation of central dopamine D1 and D2 receptors.

Authors:  M Morelli; T Mennini; A Cagnotto; G Toffano; G Di Chiara
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

6.  D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.

Authors:  S R Wachtel; X T Hu; M P Galloway; F J White
Journal:  Synapse       Date:  1989       Impact factor: 2.562

7.  Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse.

Authors:  S B Ross; D M Jackson; E M Wallis; S R Edwards
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-05       Impact factor: 3.000

8.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.

Authors:  H H Van Tol; J R Bunzow; H C Guan; R K Sunahara; P Seeman; H B Niznik; O Civelli
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

9.  Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.

Authors:  M W Hamblin; I Creese
Journal:  Life Sci       Date:  1983-05-09       Impact factor: 5.037

10.  Grooming in the mouse is stimulated by the dopamine D1 agonist SKF 38393 and by low doses of the D1 antagonist SCH 23390, but is inhibited by dopamine D2 agonists, D2 antagonists and high doses of SCH 23390.

Authors:  B S Starr; M S Starr
Journal:  Pharmacol Biochem Behav       Date:  1986-04       Impact factor: 3.533

View more
  11 in total

1.  Dopamine receptor modulation of repetitive grooming actions in the rat: potential relevance for Tourette syndrome.

Authors:  Jennifer L Taylor; Abha K Rajbhandari; Kent C Berridge; J Wayne Aldridge
Journal:  Brain Res       Date:  2010-01-28       Impact factor: 3.252

2.  Methamphetamine blunts Ca(2+) currents and excitatory synaptic transmission through D1/5 receptor-mediated mechanisms in the mouse medial prefrontal cortex.

Authors:  Betina González; Celeste Rivero-Echeto; Javier A Muñiz; Jean Lud Cadet; Edgar García-Rill; Francisco J Urbano; Verónica Bisagno
Journal:  Addict Biol       Date:  2015-04-14       Impact factor: 4.280

3.  The role of dopamine in reinforcement: changes in reinforcement sensitivity induced by D1-type, D2-type, and nonselective dopamine receptor agonists.

Authors:  Natalie A Bratcher; Valeri Farmer-Dougan; James D Dougan; Byron A Heidenreich; Paul A Garris
Journal:  J Exp Anal Behav       Date:  2005-11       Impact factor: 2.468

4.  Behavioural and physiological effects induced by an infusion of antisense to alpha(2D)-adrenoceptors in the rat.

Authors:  E S Robinson; D J Nutt; H C Jackson; A L Hudson
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions.

Authors:  J Fornaguera; J P Huston; R J Carey; R K Schwarting
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

Review 7.  The genetic factors influencing the development of trichotillomania.

Authors:  Koushik Chattopadhyay; Koushik Chatterjee
Journal:  J Genet       Date:  2012-08       Impact factor: 1.166

8.  Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C.

Authors:  S A Daly; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  The role of the dopamine D1 receptor in social cognition: studies using a novel genetic rat model.

Authors:  Judith R Homberg; Jocelien D A Olivier; Marie VandenBroeke; Jiun Youn; Arabella K Ellenbroek; Peter Karel; Ling Shan; Ruben van Boxtel; Sharon Ooms; Monique Balemans; Jacqueline Langedijk; Mareike Muller; Gert Vriend; Alexander R Cools; Edwin Cuppen; Bart A Ellenbroek
Journal:  Dis Model Mech       Date:  2016-05-19       Impact factor: 5.758

10.  Kami-shoyo-san improves ASD-like behaviors caused by decreasing allopregnanolone biosynthesis in an SKF mouse model of autism.

Authors:  Qing-Yun Guo; Ken Ebihara; Takafumi Shimodaira; Hironori Fujiwara; Kazufumi Toume; Dya Fita Dibwe; Suresh Awale; Ryota Araki; Takeshi Yabe; Kinzo Matsumoto
Journal:  PLoS One       Date:  2019-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.